Introduction
Circulating non-coding RNAs have been proposed as a new class of biomarkers and are currently being investigated for their potential in heart failure (HF).
1 -3 Several circulating miRNA have been described, mainly as diagnostic tools, but most studies so far had only small cohorts, so they lack power and may under-or overestimate the clinical correlations. 1 Cardiac remodelling is the hallmark of HF progression with characteristic activation of pathological pro-hypertrophic signalling cascades in the cardiomyocytes. MicroRNAs (MiRNAs) are important drivers of cardiac tissue remodelling 4 and may serve as a potential therapeutic target. MiR-132 has been identified as a master switch of hypertrophic remodelling and markedly increased during the early, hypertrophic MiR-132 is presented as normalized levels (arbitrary unit). ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; hsCRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure. Continuous, normally distributed variables were analyzed with ANOVA, whereas Kruskal-Wallis test was used for non-normally distributed variables. Chi-squared test was done for categorical variables.
phase of HF. 5 It regulates several key molecular targets in HF, such as the anti-hypertrophic transcription factor FoxO3, 6 the elements of intracellular calcium handling, e.g. SERCA2 and cell fate. 7 Inhibition of miR-132 in genetic or pharmacological studies has a powerful effect on reversing or preventing HF progression, 6 indicating a therapeutic utility in HF. MiRNAs are not confined to the intracellular space: they remain stable extracellularly and are found in body fluids. The origin, mechanism of passage and function of these extracellular miRNAs are poorly understood, and their relation with HF has yet to be explored. Here we analysed the circulating levels of miR-132 levels in a large HF cohort (GISSI-HF 
Methods

Patients
The GISSI-HF trial was a randomized, double-blind, placebo-controlled, multicentre study that enrolled 6975 patients with clinical evidence of chronic and stable HF [New York Heart Association (NYHA) class II-IV], irrespective of the cause and the left ventricular ejection fraction. They were randomized to receive n-3 polyunsaturated fatty acids (PUFA, 1 g daily) vs. placebo or rosuvastatin (10 mg daily) vs. placebo. The design and main results of the trial have been published previously. 8, 9 In a subset of 1237 patients recruited in 51 clinical centres, venous blood samples were collected at randomization and after 3 months of follow-up. Patients rested supine for at least 15 min before blood sampling. Blood was centrifuged at 4 ∘ C within 10 min and plasma aliquots were shipped on dry ice to a central laboratory. Samples were stored at -70 ∘ C until assayed. The present study comprises 953 patients with blood samples and miR-132 measurements available at baseline. Main clinical characteristics of the patients enrolled in the GISSI-HF trial and in the present study are shown in the Supplementary material online, Table S1 .
Measurement of miR-132
RNA was isolated from 100 μL of plasma per sample with the MiRNeasy Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Five microlitres of 1 fmol/μL Caenorhabditis elegans miR-39 (cel_miR-39) were added as an internal standard before starting the isolation procedure to check for variation of the procedure. RNA was eluted from the columns using 20 μL of water; 2.5 μL diluted RNA were used for complementary DNA synthesis with the Reverse Transcription TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems ® , Darmstadt, Germany) according to the manufacturer's instructions. The reverse transcription reaction was then diluted with water (1:3 ratio) and 2 μL were used for quantitative RT-PCR (qRT-PCR) with specific TaqMan miRNA assays (Applied Biosystems ® ). Relative miRNAs concentrations were calculated using the standard curve method generating by plotting the theshold values (Ct) against the log of the starting quantity of each dilution. The quantity was calculated from standard dilutions (1:1, 1:5, 1:25, 1:125) of a random subset of samples. The Ct value of each sample was used to calculate its level in relation to the standard curve. The expression of miR-132 was normalized to the expression of the spiked-in C. elegans miR-39 RNA. 10 The other circulating biomarkers were assayed as previously described for N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT), 11 high-sensitivity C-reactive protein (hsCRP) and pentraxin-3. 12
Statistics
Categorical variables are presented as proportions, and continuous variables as means (standard deviation), or medians [Q1-Q3] when variables were not normally distributed. Differences in clinical characteristics according to tertiles of miR-132 were compared by the chi-squared test or Fisher's exact test for categorical variables; for continuous variables we used analysis of variance (ANOVA) or non-parametric Kruskal-Wallis test. Multivariable linear regression analysis was done to identify the clinical variables independently associated with higher baseline levels of miR-132 after natural log transformation. The independent variables in the model were those significantly (P < 0.05) related in univariate analysis (Pearson correlation) with baseline miR-132 after natural log transformation. We analysed the linearity of risk between miR-132 levels and the clinical endpoints of the study (all-cause mortality, cardiovascular mortality, cardiovascular or HF hospitalization, all considered as time to first event) by restricted cubic splines (RCS), testing whether the non-linear component was statistically significant. analysed over a median follow-up of 46.2 [36.7-54.6] months. First, Kaplan-Meier curves by tertile of miR-132 concentration were reported and compared with the log-rank test. Second, baseline miR-132 concentration was considered a continuous variable for non-fatal endpoints (cardiovascular or HF hospitalization) and a continuous variable on a natural log scale for fatal outcome (all-cause mortality, cardiovascular mortality) due to non-linearity of risk. The relationship between the miRNA and outcomes was assessed by univariate Cox proportional hazard models. We used Cox multivariate models including baseline miR-132 and the demographic, clinical and echocardiographic variables that had a significant univariate relationship with outcome (P < 0.05) to establish the independent prognostic value of baseline miR-132. The assumption of proportionality of hazards was verified for all models.
The continuous net reclassification improvement (cNRI) analysis was used to test the increased discriminative prognostic value of baseline miR-132. 14 We evaluated reclassification improvement due to miR-132 on top of two multivariable models: first a model with clinical risk factors alone (model A), then a model with clinical risk factors and NT-proBNP (model B). All the models were calibrated according to the Greenwood-Nam-D'Agostino test (P > 0.05). The results are reported in terms of the overall NRI and its sub-components: event NRI and non-event NRI. knots showing the association of baseline miR-132 levels with the relative risk of all-cause mortality (P = 0.62 for non-linearity), cardiovascular mortality (P = 0.88), cardiovascular hospitalization (P = 0.65) or heart failure hospitalization (P = 0.60). Solid line and shaded area of the restricted cubic splines represent the log relative hazard and 95% confidence intervals, respectively. MiR-132 was transformed on a natural logarithmic scale for the two fatal endpoints.
Statistical analysis was done using SAS software version 9.3 (SAS Institute, Cary, NC, USA). A two-sided P-value of <0.05 was deemed to be statistically significant. Figure 1) . Patients with higher miR-132 were younger and had better renal filtration. In multivariable linear regression analysis, six variables remained independently associated with higher miR-132. By decreasing order of t-value, the strongest were: younger age, lower serum creatinine concentration, NYHA III or IV, and ischaemic aetiology of HF (see Supplementary material online, Table S2 ). When circulating biomarkers (NT-proBNP, hsCRP, pentraxin-3) were added to the previous model, only lower hsCRP levels remained associated with higher miR-132 (see Supplementary material online, 
Results
Clinical characteristics associated with miR-132 levels
Effect of randomized treatments on miR-132 levels
Neither n-3 PUFA (least-squares mean ± SEM for 3-month absolute changes in miR-132 levels adjusted for baseline miR-132 levels: 0.016 ± 0.038 vs. 0.047 ± 0.037 for placebo, P-value for ANCOVA = 0.57) nor rosuvastatin (least-squares mean ± SEM: -0.030 ± 0.047 vs. 0.013 ± 0.048 for placebo, P-value for ANCOVA = 0.52) had any effect on miR-132 levels after 3 months of treatment. Likewise, there was no significant interaction between baseline miR-132 (below or above median) and randomized treatments (n-3 PUFA or rosuvastatin) with the four clinical endpoints (data not shown).
Prognostic value of baseline miR-132
Median Figure 2 , Figure 3 Kaplan-Meier curves for clinical outcomes by tertiles of baseline miR-132. Estimated probability of events by tertiles of baseline miR-132 for the four clinical endpoints. T1 < 0.25, T2 0.25-0.65, T3 > 0.65. The number of patients at risk each year is shown below the graph for the three tertiles. P-value for log-rank test. HF, heart failure.
whereas Figure 3 shows the Kaplan-Meier survival curves by tertiles of baseline miR-132 for these four endpoints.
There was an inverse stepwise increase in event rates for total or cardiovascular mortality and for first HF admission to hospital. The independent association of baseline miR-132 levels with the four clinical endpoints was evaluated with Cox proportional hazard models. In univariate analysis, miR-132 was associated with all endpoints except cardiovascular admission to hospital (Figure 4 
miR-132 improves risk prediction
We assessed the ability of miR-132 to improve risk prediction with the cNRI. MiR-132 was added on top of two nested multivariable models that included clinical risk factors, with or without baseline NT-proBNP concentration. The addition of baseline miR-132 -All-cause mortality: age, left ventricular ejection fraction, NYHA class, ischaemic aetiology of HF, heart rate, systolic and diastolic blood pressure, diabetes, atrial fibrillation, chronic obstructive pulmonary disease, prescription of beta-blockers, diuretics, digitalis, serum concentrations of creatinine, total cholesterol and triglycerides.
-CV mortality: age, left ventricular ejection fraction, NYHA class, heart rate, systolic and diastolic blood pressure, diabetes, atrial fibrillation, chronic obstructive pulmonary disease, prescription of beta-blockers, diuretics, digitalis, serum concentrations of creatinine, total cholesterol and triglycerides.
-HF hospitalization: age, NYHA class, heart rate, systolic and diastolic blood pressure, diabetes, hypertension, atrial fibrillation, chronic obstructive pulmonary disease, prescription of beta-blockers, diuretics, digitalis, serum concentrations of creatinine.
correctly re-classified HF hospitalizations (cNRI 0.205, P = 0.001; Table 2 ), but was less effective for cardiovascular mortality (cNRI 0.141, P = 0.08). In particular, it boosted the sensitivity of the identification of patients with HF hospitalization (correct classification of events improved by 40.7%), to the detriment of a 20.2% loss of correct identification of non-events.
Discussion
Here, for the first time using a large cohort of patients with chronic HF enrolled in a multicentre, randomized clinical trial, we show that plasma levels of miR-132, a miRNA involved in . pathological cardiac hypertrophy (i) were inversely related to age or renal function, (ii) were not influenced by a 3-month treatment with n-3 PUFA or a statin, (iii) predicted long-term cardiovascular mortality and readmission to hospital for worsening of HF, and (iv) improved risk prediction over clinical risk factors for the latter outcome.
The expression of a number of specific miRNAs is up-or down-regulated in the failing human heart. 5 Among them, the miR-212/132 cluster plays a central role in the pathophysiology of HF. In experimental models the cluster induces cardiac hypertrophy, a risk factor for the transition to HF, through direct regulation of transcription factor FoxO3 expression 6 and by interacting with angiotensin II signalling.
15 Non-coding regulatory RNAs, including miRNAs, may be released into the extracellular space and so they can be found in almost all body fluids. 1, 16 Several circulating miRNAs have been described as potential biomarkers for diagnosis, monitoring response to therapy, and for prognostic purposes in cardiovascular pathologies, including acute and chronic HF.
1-3,17-21
Despite this biological plausibility, clinical data on the potential of circulating miR-132 as a biomarker in cardiovascular diseases are still scarce.
17
MiR-132 has been identified in a diagnostic biomarker study for unstable angina. 22 Here we examined the miRNA signature profile from serum samples. 22 After profiling and validation, a panel of three miRNAs (miR-132, miR-150, and miR-186) demonstrated a strong discriminating power, even higher than that of troponin I alone or in combination with the panel, between patients with unstable angina and patients with non-coronary chest pain.
In a cohort of 1112 patients with documented coronary artery disease followed for 4 years, circulating miR-132 (among seven other candidate miRNAs) predicted cardiovascular death, with incremental discrimination. 23 However, it is not known whether miR-132 outperformed other circulating biomarkers (including other measured miRNAs) or whether it improved risk prediction beyond clinical factors or scores using metrics like reclassification analyses. To the best of our knowledge, no data are yet available on the prognostic value of circulating miR-132 in clinical studies with chronic HF patients.
Plasma levels of miR-132 rose with HF severity (NYHA class and ischaemic aetiology) but were surprisingly lower in elderly patients and those with depressed renal glomerular filtration, two conditions that are usually associated with worse HF. These observations suggest that different factors influence the steady-state circulating levels of miR-132 in different subcohorts of chronic HF. Circulating miRNAs are bound to plasma proteins such as albumin. The relationship between renal impairment and proteinuria is well documented, so the low levels of miR-132 might also be explained by the loss of carrier plasma proteins in patients with a low renal glomerular filtration rate. On the other hand, higher levels of miR-132 invariably predicted lower rates of fatal (all-cause or cardiovascular death) or non-fatal events (admission to hospital for cardiovascular or HF reasons). This is internally consistent with the inverse association of miR-132 levels with plasma concentrations of NT-proBNP or hscTnT, two benchmark prognostic markers in chronic HF. In our study, lower circulating miR-132 levels were associated with some fatal and non-fatal endpoints. They improved risk prediction, especially for HF hospitalization, beyond traditional risk factors in chronic HF (advanced age, reduced left ventricular ejection fraction, more severe symptoms, co-morbidities and impaired renal function) and a strong predictor like natriuretic peptide. Heart failure hospitalization is a heavy health and economic burden since HF accounts for 1-3% of all US and European hospital admissions and its cost is driven by hospitalization. 24, 25 In fact, despite a tendency to a decline in admissions for HF in the past two decades, readmission rates after an index admission have remained unchanged or tended to raise, with roughly one in four patients readmitted within 30 days and nearly half within 6 months. 26 Of note, baseline miR-132 levels were not independently associated with the two co-primary endpoints of the GISSI-HF trial, time to death, and time to death or admission to hospital for cardiovascular reasons.
Given the post-hoc feature of the present analysis, our results should not be over-emphasized and are to be read as hypothesis-generating. The translation of disease-associated circulating miRNA patterns into clinical useful biomarkers has been hampered by lack of consistency. Recent efforts have led to the recommendations and minimum reporting requirements for circulating non-coding RNAs. The areas of sample handling, processing, analytics and reporting are well covered, but we still lack a global, standardized method for normalizing miRNA levels (housekeeping or reference genes). Further studies assessing potential biomarkers such as miR-132 need to be carefully planned and executed, based on the recommendations, with special attention to the transparency of the normalization method. Early detection with circulating biomarkers of the risk of future hospitalization for HF could potentially be helpful to intensify strategies aimed at reducing readmission rates. Table S1 . Main clinical characteristics of the patients enrolled in the GISSI-HF trial and in the present study. Table S2 . Variables independently associated with higher baseline levels of miR-132.
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